Antibody-Drug Conjugates (ADCs): A Novel Therapy for Triple-Negative Breast Cancer (TNBC)

Gaurav Gupta^{1

2}, Md Sadique Hussain³, Kumud Pant^{4

5}, Haider Ali^{6

7}, Riya Thapa³, Asif Ahmad Bhat³

Affiliations

¹ Chitkara College of Pharmacy, Chitkara University, Rajpura, Chandigarh, India.
² Centre of Medical and Bio-allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates.
³ Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, Uttarakhand 248007, India.
⁴ Graphic Era (Deemed to be University) Clement Town Dehradun- 248002, India.
⁵ Graphic Era Hill University, School of Pharmaceutical Sciences, Clement Town Dehradun- 248002, India.
⁶ Centre for Global Health Research, Saveetha Medical College, Saveetha Institute of Medical and Technical Sciences, Saveetha University, India.
⁷ Department of Pharmacology, Kyrgyz State Medical College, Bishkek, Kyrgyzstan.

Gaurav Gupta et al. Curr Cancer Drug Targets. 2025.

. 2025;25(2):108-112.

doi: 10.2174/0115680096343056240828190900.

Gaurav Gupta^{1

2}, Md Sadique Hussain³, Kumud Pant^{4

5}, Haider Ali^{6

7}, Riya Thapa³, Asif Ahmad Bhat³

¹ Chitkara College of Pharmacy, Chitkara University, Rajpura, Chandigarh, India.
² Centre of Medical and Bio-allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates.
³ Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, Uttarakhand 248007, India.
⁴ Graphic Era (Deemed to be University) Clement Town Dehradun- 248002, India.
⁵ Graphic Era Hill University, School of Pharmaceutical Sciences, Clement Town Dehradun- 248002, India.
⁶ Centre for Global Health Research, Saveetha Medical College, Saveetha Institute of Medical and Technical Sciences, Saveetha University, India.
⁷ Department of Pharmacology, Kyrgyz State Medical College, Bishkek, Kyrgyzstan.

No abstract available

Keywords: Antibody-drug conjugates; Sacituzumab govitecan; Trop2 antigen; clinical trial.; triple-negative breast cancer.

References

1. Abdus Subhan M.; Torchilin V.P.; Advances with antibody-drug conjugates in breast cancer treatment. Eur J Pharm Biopharm 2021,169,241-255 - DOI - PubMed
1. Ritchie M.; Tchistiakova L.; Scott N.; Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. MAbs 2013,5(1),13-21 - DOI - PubMed
1. Mahalingaiah P.K.; Ciurlionis R.; Durbin K.R.; Yeager R.L.; Philip B.K.; Bawa B.; Mantena S.R.; Enright B.P.; Liguori M.J.; Van Vleet T.R.; Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates. Pharmacol Ther 2019,200,110-125 - DOI - PubMed
1. Giugliano F.; Corti C.; Tarantino P.; Michelini F.; Curigliano G.; Bystander effect of antibody–drug conjugates: Fact or fiction? Curr Oncol Rep 2022,24(7),809-817 - DOI - PubMed
1. Maqbool M.; Bekele F.; Fekadu G.; Treatment strategies against triple-negative breast cancer: An updated review. Breast Cancer (Dove Med Press) 2022,14,15-24 - DOI - PubMed